Navigation Links
Frost & Sullivan Recognizes Waters Corporation for Its Pioneering, High Customer Value Analytical Instrumentation Product, SYNAPT HDMS
Date:8/18/2008

system was designed with the end-user in mind. The system's novel separation capability has fueled demand from both academic and commercial segments. For example, academicians studying structural biology research who are challenged with the dynamic nature of living cells and interaction of molecules within those cells embrace SYNAPT HDMS' ability to differentiate and measure molecular conformations (shapes).

Additionally, the system provides the power to further separate mixtures, enhance detection limits by removing background noise and interferences, and extract more information from fragmentation studies. As a result, there has been a rapid adoption of the system among commercial groups who seek to further characterize their proprietary biopharmaceuticals and pharmaceutical molecules within the discovery, commercialization and marketing phases. Clearly, SYNAPT HDMS is a breakthrough technology that makes innovation and discoveries possible.

Waters' dedication to innovation is obvious through its 50-year history and its line of analytical solutions. Mass spectrometers, including the SYNAPT HDMS, are often integrated with complementary instruments, such as the ACQUITY(R) UltraPerformance LC(R) liquid chromatography (UPLC(R)) system, a 2007 Frost & Sullivan Product Innovation award recipient. Additionally, these total systems require sophisticated software packages to maximize the collection and analysis of scientific data, such as Waters MassLynx and NuGenesis Scientific Data Management System (SDMS). These total systems are used throughout the drug discovery and development process, starting with studies of disease, moving to identification of potential therapeutic molecules, then to clinical trials and throughout the manufacturing process.

"Waters has demonstrated excellence in product innovation in the North American analytical instrumentation and services market in life sciences by developing intelligent systems that deliver high levels of
'/>"/>

SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Direct From Beijing, 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Womens Cancer Awareness Special, Frosted Pink With A Twist
2. Kingfisher Healthcare (KFH) Wins Prestigious Frost & Sullivan Best Practices Award
3. Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy
4. Draeger Receives Frost & Sullivan Consumer Award for Respiratory Protection
5. Therapy Could Save Limbs After Frostbite
6. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
7. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. MedApps Receives Prestigious Frost & Sullivan Award
10. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
11. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 4Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 2Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 3Health News:AHF Launches 'Public Health Division' 2Health News:AHF Launches 'Public Health Division' 3Health News:AHF Launches 'Public Health Division' 4Health News:'Making the Case:' special double issue of Critical Inquiry 2Health News:'Making the Case:' special double issue of Critical Inquiry 3Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2